Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DF6002 Monotherapy and Combination with Nivolumab in Advanced Solid Tumors
NCT04423029Phase 1Completed
- Sponsor
- Dragonfly Therapeutics
- Start
- Jul 2020
- Primary completion
- Nov 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Cytokines & Interferons
- Countries
- 4
01
Overview
Phase 1, open-label trial of DF6002 in solid tumor, melanoma and non-melanoma skin cancer (NMSC) (6 arms), sponsored by Dragonfly Therapeutics. Primary endpoints: Dose-Limiting Toxicities at 3 weeks and Overall Response Rate at 2 years. Started Jul 2020; status: completed.
02
Drugs
DF6002
03
Conditions
solid tumormelanomanon-melanoma skin cancer (NMSC)
Beyond the preview
Go deeper on NCT04423029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04423029.